# CD19-Synthetic T Cell Antigen Receptor(STAR)-T in B-cell Malignancies Patients

> **NCT03953599** · PHASE1 · COMPLETED · sponsor: **Hebei Yanda Ludaopei Hospital** · enrollment: 18 (actual)

## Conditions studied

- B Cell Malignancy

## Interventions

- **BIOLOGICAL:** CD19-STAR-T cells

## Key facts

- **NCT ID:** NCT03953599
- **Lead sponsor:** Hebei Yanda Ludaopei Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-07-01
- **Primary completion:** 2021-07-01
- **Final completion:** 2021-12-31
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2022-02-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03953599

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03953599, "CD19-Synthetic T Cell Antigen Receptor(STAR)-T in B-cell Malignancies Patients". Retrieved via AI Analytics 2026-09-08 from https://api.ai-analytics.org/clinical/NCT03953599. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*